Seres Therapeutics Announces Research Collaboration with Mayo Clinic to Identify Microbiome Therapeutics for Primary Sclerosing Cholangitis, Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Under the terms of the agreement, Mayo Clinic Professor
“Mayo Clinic is conducting pioneering research to further characterize
the microbiome signatures associated with serious inflammatory liver
diseases, including PSC,” said
About Seres Therapeutics
About Non-Alcoholic Steatohepatitis (NASH) and Primary Sclerosing Cholangitis (PSC)
NASH is a chronic liver disease affecting approximately 2 to 3% of the U.S. population. In patients with NASH, the liver is characterized by accumulation of fat, inflammation and tissue damage. NASH can lead to fibrosis and ultimately cirrhosis, in which the liver is permanently damaged, and is a major underlying cause of liver transplant.
PSC is a serious chronic disease characterized by inflammation of the bile ducts, which carry the digestive liquid bile from the liver to the small intestine. In PSC, inflammation causes bile duct tissue injury and dysfunction that can lead to serious liver damage.
There are no approved therapies for NASH or PSC.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the identification and development of microbiome therapeutic candidates, including those for PSC, NASH, or other indications.
These forward-looking statements are based on management’s current
expectations. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements,
including, but not limited to, the following: we have incurred
significant losses, are not currently profitable and may never become
profitable; our need for additional funding, which may not be available;
our limited operating history; the unpredictable nature of our
development efforts for marketable drugs; the unproven approach to
therapeutic intervention of our microbiome therapeutics; the lengthy and
expensive process of clinical drug development, which has an uncertain
outcome; potential delays in enrollment of patients which could affect
the receipt of necessary regulatory approvals; potential delays in
regulatory approval, which would impact the ability to commercialize our
product candidates and affect our ability to generate revenue; any fast
track, Breakthrough Therapy or PRIME designation may not lead to faster
development, regulatory approval or marketing approval; our possible
inability to receive orphan drug designation should we choose to seek
it; our reliance on third parties to conduct our clinical trials and the
potential for those third parties to not perform satisfactorily; our
reliance on third parties to manufacture our product candidates, which
may delay, prevent or impair our development and commercialization
efforts; our lack of experience in manufacturing our product candidates;
the potential failure of our product candidates to be accepted on the
market by the medical community; our lack of experience selling,
marketing and distributing products and our lack of internal capability
to do so; failure to compete successfully against other drug companies;
potential competition from biosimilars; failure to obtain marketing
approval internationally; post-marketing restrictions or withdrawal from
the market; anti-kickback, fraud, abuse, and other healthcare laws and
regulations exposing us to potential criminal sanctions; recently
enacted or future legislation; compliance with environmental, health,
and safety laws and regulations; protection of our proprietary
technology; protection of the confidentiality of our trade secrets;
changes in
Reference:
1 Tabibian JH et al., Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis, Hepatology, 2016.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160606005393/en/
Source:
IR and PR Contact:
Seres
Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor
Relations and Corporate Communications
Ctanzi@serestherapeutics.com